A Study: Pure CBD as Single-agent for Solid Tumor.
Launched by HADASSAH MEDICAL ORGANIZATION · Oct 1, 2014
Trial Information
Current as of April 26, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Confirmed solid cancer
- • Approved license for using cannabis (from the ministry of health: Israel)
- • Progression of all the available standard therapy / unfit to standard therapy according to oncologist's view
- • Measurable disease as determined by RECIST
- • Life expectancy of at least 6 months
- • Eastern Cooperative Oncology Group (ECOG) performance status \< or = 2
- • Aged 18 years old and more
- Exclusion Criteria:
- • Received cannabis therapy for any indication
- • Previous systemic therapy of less than 3 weeks prior to and, if present, any acute toxicity \> grade 1.
- • Clinically significant cardiac disease or any history of psychosis
- • Pregnancy or breast feeding
About Hadassah Medical Organization
Hadassah Medical Organization (HMO) is a leading healthcare institution based in Jerusalem, Israel, renowned for its commitment to advancing medical research and improving patient care. As a prominent clinical trial sponsor, HMO leverages its state-of-the-art facilities and multidisciplinary expertise to conduct innovative research across various therapeutic areas. The organization is dedicated to fostering collaboration between clinical researchers, healthcare professionals, and academic institutions, ensuring the highest standards of ethical practice and scientific rigor. HMO's mission is to translate groundbreaking research into effective treatments, ultimately enhancing health outcomes for diverse populations both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Hadas Lemberg, PhD
Study Chair
Hadassah Medical Organization
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials